313682-08-5

313682-08-5 structure
313682-08-5 structure
  • Name: Brecanavir
  • Chemical Name: [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[1,3-benzodioxol-5-ylsulfonyl(2-methylpropyl)amino]-3-hydroxy-1-[4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl]butan-2-yl]carbamate
  • CAS Number: 313682-08-5
  • Molecular Formula: C33H41N3O10S2
  • Molecular Weight: 703.82300
  • Catalog: Signaling Pathways Metabolic Enzyme/Protease HIV Protease
  • Create Date: 2017-10-02 15:34:02
  • Modify Date: 2026-07-16 13:00:10
  • Brecanavir (GW640385) is a novel, potent HIV protease inhibitor.

Name [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[1,3-benzodioxol-5-ylsulfonyl(2-methylpropyl)amino]-3-hydroxy-1-[4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl]butan-2-yl]carbamate
Synonyms GW-640385X
brecanavir
CHEMBL206031
Cbamic acid, N-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-[[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]methyl]propyl]-, (3R,3aS,6-hexahydrofuro[2,3-b]furan-3-yl ester
GW0385
GW-640385
UNII-E367I8C7FI
[(1R,5S,6R)-2,8-dioxabicyclo[3.3.0]oct-6-yl] N-[(2S,3R)-4-(benzo[1,3]dioxol-5-ylsulfonyl-(2-methylpropyl)amino)-3-hydroxy-1-[4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl]butan-2-yl]cbamate
2fdd
GW-0385
2fde
Density 1.43g/cm3
Molecular Formula C33H41N3O10S2
Molecular Weight 703.82300
Exact Mass 703.22300
PSA 191.60000
LogP 5.33740
Index of Refraction 1.641

~%

313682-08-5 structure

313682-08-5

Literature: Miller, John F.; Andrews, C. Webster; Brieger, Michael; Furfine, Eric S.; Hale, Michael R.; Hanlon, Mary H.; Hazen, Richard J.; Kaldor, Istvan; McLean, Ed W.; Reynolds, David; Sammond, Douglas M.; Spaltenstein, Andrew; Tung, Roger; Turner, Elizabeth M.; Xu, Robert X.; Sherrill, Ronald G. Bioorganic and Medicinal Chemistry Letters, 2006 , vol. 16, # 7 p. 1788 - 1794

~%

313682-08-5 structure

313682-08-5

Literature: Miller, John F.; Andrews, C. Webster; Brieger, Michael; Furfine, Eric S.; Hale, Michael R.; Hanlon, Mary H.; Hazen, Richard J.; Kaldor, Istvan; McLean, Ed W.; Reynolds, David; Sammond, Douglas M.; Spaltenstein, Andrew; Tung, Roger; Turner, Elizabeth M.; Xu, Robert X.; Sherrill, Ronald G. Bioorganic and Medicinal Chemistry Letters, 2006 , vol. 16, # 7 p. 1788 - 1794

~%

313682-08-5 structure

313682-08-5

Literature: Miller, John F.; Andrews, C. Webster; Brieger, Michael; Furfine, Eric S.; Hale, Michael R.; Hanlon, Mary H.; Hazen, Richard J.; Kaldor, Istvan; McLean, Ed W.; Reynolds, David; Sammond, Douglas M.; Spaltenstein, Andrew; Tung, Roger; Turner, Elizabeth M.; Xu, Robert X.; Sherrill, Ronald G. Bioorganic and Medicinal Chemistry Letters, 2006 , vol. 16, # 7 p. 1788 - 1794

~%

313682-08-5 structure

313682-08-5

Literature: Miller, John F.; Andrews, C. Webster; Brieger, Michael; Furfine, Eric S.; Hale, Michael R.; Hanlon, Mary H.; Hazen, Richard J.; Kaldor, Istvan; McLean, Ed W.; Reynolds, David; Sammond, Douglas M.; Spaltenstein, Andrew; Tung, Roger; Turner, Elizabeth M.; Xu, Robert X.; Sherrill, Ronald G. Bioorganic and Medicinal Chemistry Letters, 2006 , vol. 16, # 7 p. 1788 - 1794
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.